In a landmark move, the Trump administration has launched a sweeping crackdown on misleading pharmaceutical advertisements, the first major enforcement effort since direct-to-consumer drug ads were legalized in 1997.
FDA Commissioner Dr. Marty Makary recently spoke with Full Measure about the unprecedented effort, stating that the agency is sending “thousands” of enforcement letters targeting deceptive promotions across TV, social media, and online platforms.
The U.S. is one of only two countries allowing such ads (the other is New Zealand). Makary says the commercials often downplay serious risks, present false information, or mislead viewers by showcasing happy, dancing patients. He says FDA enforcement has been notoriously lax for decades, with FDA violation letters to drug companies dropping from 130 annually in the late 1990s to zero in 2024.
The new plan targets not just TV but also social media influencers and online pharmacies.
Join the conversation as a VIP Member